药明康德（603259）(02359)发布公告，该公司于2025年8月12日斥资2799.23万元人民币回购30.79万股 股份，每股回购价格为90.13-91.6元人民币。 ...

格隆汇8月12日丨药明康德(02359.HK)发布公告，2025年8月12日耗资2799.23万元人民币回购30.79万股 A股，回购价格每股90.13-91.6元。 ...

智通财经APP讯，药明康德(02359)发布公告，该公司于2025年8月12日斥资2799.23万元人民币回购30.79 万股股份，每股回购价格为90.13-91.6元人民币。 ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1002173创新医疗20.599.992.50亿元7.9%2002622皓宸 医疗3.569.881.12亿元34.67%3301096百诚医药60.512.073461.18万元8.02%4605186健麾信息 23.761.242536.86万元16.7%5002044美年健康5.260.192272.94万元5.8%6300759康龙化成28.96- 0.171772.85万元1.66%7000516国际医学5.450.741482.03万元6.9%8301033迈普医学88.810.38858.71万元 4.1%9301267华厦眼科20.83-0.38853.90万元5.56%10002219新里程2.2-0.9715.88万元5.51% 主力资金净流出居前的分别为药明康德（1.53亿元）、爱尔眼科（1.14亿元）、成都先导（7774.55万 元）、润达医疗（6132.92万元）、昭衍新药（5117.86万元）。 8月12日，医疗服务行业上涨0.07%，今日主力资金流出2.27亿元，成分股17只上涨，25只下跌。 ...

公募基金二季报本周进入密集披露期，部分头部基金及知名基金经理的调仓动向也备受市场关注。 综合来看，各家基金在二季度保持了高仓位运作，新能源产业链、医药消费等成为关注重点。 此外，睿远基金傅鹏博管理的基金则对光伏行业板块个股更为关注。综合季报，通威股份、迈为股 份等新晋十大重仓股，大族激光、先导智能等退出前十大重仓股序列；由傅鹏博、朱璘管理的睿远成长 价值混合基金前十大重仓股为三安光电、中国移动、立讯精密、东方雨虹、万华化学、通威股份、吉利 汽车、沃森生物、迈为股份、国瓷材料。相比一季度，该基金新进持仓了通威股份、吉利汽车、迈为股 份，而先导智能、大族激光、卫宁健康则被调出十大重仓股序列；广发基金刘格菘持仓结构没有出现大 幅调整。其前十大重仓股当中，亿纬锂能、龙佰集团的持仓量不变，国联股份、福莱特分别新晋成为第 七大重仓股和第九大重仓股。另外，晶澳科技、隆基绿能、锦浪科技等多只个股持股数量均较一季度末 有所增长。 Wind数据显示，截至7月20日记者发稿时，已经有多家基金公司旗下1338只股票型开放式基金（未 合并A/C）发布了二季度报告，其中不乏头部基金公司和张坤、刘格菘、傅鹏博、李晓星等知名基金经 理。易方 ...

不到一个半月，药明康德连续抛出了两份10亿元股份回购计划。 3月9日，药明康德启动了第二轮10亿元股份回购计划，继前次于2月5日完成10亿元A股股份回购后，为 进一步维护公司价值和股东权益，公司拟继续通过上海证券交易所系统以集中竞价交易方式回购A股股 票，拟回购资金总额为10亿元，回购完成之后全部予以注销并减少注册资本。 本次回购股份价格不超过83.33元/股（含），回购价格较3月8日收盘价高出60.74%。按回购价格上限 83.33元/股（含）测算，预计本次回购股份数量约为1200.05万股。 萨摩耶云科技集团首席经济学家郑磊向《证券日报》记者表示："回购是提升上市公司股票价值的主要 举措之一，尤其是上市公司将回购的股票注销，直接提高了每股含金量和每股潜在收益水平，同时也给 投资者一个信号，即公司当前股价低于其内在价值，未来可能仍有上升空间。" 药明康德在公告中提到，鉴于截至2024年3月1日公司A股股票连续20个交易日内股票收盘价格跌幅累计 达到20%。3月8日，公司召开第三届董事会第十次会议审议通过《关于以集中竞价交易方式回购公司A 股股份的议案》，同意实施本次回购股份方案。 公司股价不振，从消息面上来 ...

Core Viewpoint - The enthusiasm for share buybacks among listed companies has surged in 2023, with a significant increase in the number of buyback plans and the total amount allocated for these buybacks, reflecting a proactive approach to capital management and market confidence [1][2][3]. Group 1: Share Buyback Trends - As of March 16, 2023, 821 A-share companies have announced 830 buyback plans, with a total buyback limit exceeding 90 billion yuan [1]. - The number of companies engaging in "cancellation-type" buybacks has increased, with 57 new plans announced, indicating a focus on maintaining and enhancing stock prices [1][2]. - The total disclosed amount for buyback cancellations has reached 22.7 billion yuan, surpassing the total for the entire year of 2023 [2]. Group 2: Regulatory Support and Market Impact - The China Securities Regulatory Commission (CSRC) has expressed strong support for share buybacks, particularly cancellation-type buybacks, as a means to enhance shareholder returns and stabilize the market [2][3]. - New regulatory guidelines encourage companies to adopt buyback strategies, including the integration of buyback amounts into dividend payout calculations [2][3]. - The implementation of these guidelines is expected to lead to an increase in buyback frequency and amounts, thereby improving market confidence and stability [3]. Group 3: Leading Companies and Market Response - Major companies with market capitalizations exceeding 100 billion yuan, such as WuXi AppTec and Midea Group, are actively engaging in cancellation-type buybacks, setting a precedent for other firms [4][5]. - The announcement of substantial buyback plans has led to immediate positive stock price reactions, indicating investor approval and confidence in these strategies [5]. - The actions of leading companies are expected to have a demonstrative effect, encouraging other firms to adopt similar practices to enhance the overall investment environment [5].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

药明康德（603259）(02359)公布，2025年8月11日耗资约2799.56万元回购30.7万股A股股份。 ...